An interventional study of Electrophysiological study (EP study) and ePatch (extended Holter Monitoring) in Aortic Stenosis, Transcatheter Aortic Valve Implantation and Conduction Disturbances, sponsored by Institut d'Investigació Biomèdica de Bellvitge. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-01.
Sponsored by Institut d'Investigació Biomèdica de Bellvitge · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Aortic Valve Stenosis with a site in Spain — 25 open to participants now, 32 under way, 1 of them phase 3. Aortic Valve Stenosis · Spain.
Among the 83 studies in Aortic Valve Stenosis with a site in Spain, this one is the 19th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2024, is one of 26 with no phase, reaches primary completion later than 11 of the 31 other live ones, and was the 70th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →25 of the 83 studies in Aortic Valve Stenosis with a site in Spain are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18+
Fundación EPIC · Sites in Spain
Ages 18+
Biosensors Europe SA · Sites in Spain
Ages 18+
Ceric Sàrl · Sites in Spain, Austria, Estonia and 11 more countries
Ages 65–75
Shanghai MicroPort CardioFlow Medtech Co., Ltd. · Sites in Spain, Ireland, Italy and 2 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 7
First in 2006; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 209 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 209 across the 37 interventional studies, 373 across the 46 observational. Of the 42 that completed or were terminated, 9 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 83 have an industry lead sponsor. The 10 most frequent:
Institut d'Investigació Biomèdica de Bellvitge is the lead sponsor of 19 studies on the registry; 9 are open to participants now.
Institut d'Investigació Biomèdica de Bellvitge has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05758909Fundación EPICEvaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation | 2026-12-01 |
| NCT06833762Hospital Clinic of BarcelonaClinical and CPET Parameters That Predict Improvement in Functional Capacity After TAVI | 2027-06 |
| NCT05283356Fundacin Biomedica Galicia SurSingle Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation | 2027-06-30 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
| NCT06049654Fundación EPICComparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 83 studies in Aortic Valve Stenosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The management of patients with conduction disturbances (CDs) after transcatheter aortic valve implantation (TAVI) is unclear, especially in those with de novo electrocardiographic CDs (ECG-CDs) such as left bundle branch block.
In this study, the investigators will evaluate the incidence of retrogradation of infra-Hisian CDs in patients with de novo ECG-CDs and positive electrophysiological study (EPS) 3-7 days following TAVI. In addition, the investigators will evaluate the need for cardiac pacing and the incidence of clinical events in patients with negative EPS performed 3-7 days following TAVI.
In this multicenter, longitudinal, prospective study, patients with clinical indication of EP study due to new-onset ECG-CDs after TAVI will be included. A permanent pacemaker will be implanted in patients with positive EPS and a second EPS will be performed in 30-45 days. Additionally, these patients will undergo 4-week continuous monitoring using the ePatch (Philips) long-term Holter recorder, to identify episodes of paroxysmal complete atrioventricular block. Patients with negative EP study will undergo clinical follow-up and continuous monitoring for 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Permanent pacemaker implantation. Continuous ECG monitoring during 4 weeks. Second EP study 30-45 days after TAVI.
Diagnostic Test: Electrophysiological study (EP study) · Diagnostic Test: ePatch (extended Holter Monitoring)
Continuous ECG monitoring during 4 weeks.
Diagnostic Test: ePatch (extended Holter Monitoring)
Electrophysiological study: A second EP study 30-45 days after TAVI will be performed in the group of patients with positive EP study 3-7 days after TAVI.
Continuous cardiac rhythm monitoring using the ePatch (Philips) will be performed during 4 weeks after TAVI
Incidence of retrogradation
1. Patients with positive EP: Evaluate the incidence of retrogradation of infra-Hisian conduction disturbance at 30-45 days following TAVI.
Time frame: 30 days
Need for cardiac pacing (incidence of advanced atrioventricular block)
2. Patients with negative EP: Evaluate the rate of patients in need for cardiac pacing (incidence of clinical events related to advanced atrioventricular block).
Time frame: 30 days
Plan to share: Yes — Study procotol and ICF will be shared trough PI request during the duration of the study
Supporting information: Study protocol, Informed consent form
Time frame: During the duration of the study
Access criteria: Request to the PI
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2025, 18 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 18 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut d'Investigació Biomèdica de Bellvitge